The Experts below are selected from a list of 285 Experts worldwide ranked by ideXlab platform
Isao Nagaoka - One of the best experts on this subject based on the ideXlab platform.
-
Recent aspects of the anti-inflammatory actions of Glucosamine
Carbohydrate Polymers, 2011Co-Authors: Isao Nagaoka, Shin Yomogida, Mamoru Igarashi, Y. Ju, Koji SakamotoAbstract:Glucosamine, a naturally occurring amino monosaccharide, is present in the connective and cartilage tissues as a component of glycosaminoglycans. Thus, Glucosamine has been widely used to treat osteoarthritis, a joint disease characterized by cartilage degeneration, in humans. In addition, Glucosamine is expected to exert an anti-inflammatory action, since Glucosamine suppresses inflammatory cell activation. To further extend the anti-inflammatory actions of Glucosamine, we investigated the effects of Glucosamine on synovial cells, endothelial cells and intestinal epithelial cells using in vitro and in vivo systems. Firstly, Glucosamine suppressed the IL-1β-induced activation of synovial cells in vitro. Furthermore, Glucosamine administration repressed synovial cell hyperplasia, cartilage destruction and inflammatory cell infiltration in rat adjuvant arthritis. Secondary, Glucosamine suppressed the TNF-α-induced activation of intestinal epithelial cell HT-29 in vitro. In addition, Glucosamine administration improved the clinical symptoms, and colonic inflammation and tissue injury in dextran sulfate sodium-induced colitis in rats. Finally, Glucosamine suppressed the TNF-α-induced activation of endothelial cells in vitro. Moreover, Glucosamine administration repressed the formation of atherosclerotic lesion and infiltration of inflammatory cells into the lesion in spontaneously hyperlipidemic mice B6 KOR Aposhl. Together these observations support the idea that Glucosamine can function as not only a chondroprotective agent but also an anti-inflammatory molecule in the body.
-
Inhibitory action of Glucosamine on platelet activation in guinea pigs.
Inflammation Research, 2005Co-Authors: J. F. Lu-suguro, Koji Sakamoto, Isao NagaokaAbstract:Objective: Glucosamine, a naturally occurring amino monosaccharide, has been used to treat or prevent osteoarthritis in humans. Recently, we have revealed that Glucosamine inhibits platelet activation in vitro. However, the effect of in vivo administration of Glucosamine has not yet been clarified. In this study, we administered Glucosamine orally to guinea pigs and examined its effects on platelet functions.
-
Inhibitory action of Glucosamine on platelet activation in guinea pigs
Inflammation Research, 2005Co-Authors: J. F. Lu-suguro, Koji Sakamoto, Isao NagaokaAbstract:Objective: Glucosamine, a naturally occurring amino monosaccharide, has been used to treat or prevent osteoarthritis in humans. Recently, we have revealed that Glucosamine inhibits platelet activation in vitro . However, the effect of in vivo administration of Glucosamine has not yet been clarified. In this study, we administered Glucosamine orally to guinea pigs and examined its effects on platelet functions. Materials and methods: Glucosamine hydrochloride solution (0.5%, 5 mg/ml) was administered orally to guinea pigs ad libitum for 22 days, and platelet rich plasma was collected to evaluate platelet functions in vitro . Guinea pigs received an average of 400 mg Glucosamine/animal/day. Results: Glucosamine-administration suppressed platelet aggregation in response to ADP by 51% ( p
-
Glucosamine, a naturally occurring amino monosaccharide, suppresses the ADP-mediated platelet activation in humans
Inflammation Research, 2004Co-Authors: S Suguro, Y. Tsutsumi-ishii, Kazuhisa Iwabuchi, Koji Sakamoto, Isao NagaokaAbstract:Objective: To evaluate the anti-thrombotic action of Glucosamine, a naturally occurring amino monosaccharide, platelets were stimulated with ADP in the presence of Glucosamine, and its effects on platelet functions were examined. Materials and Methods: Human platelet-rich plasma was stimulated with 2.5 μM ADP in the presence of Glucosamine (0.01 ~ 1 mM) or other aminosugars (N-acetyl-Glucosamine, galactosamine or N-acetyl-galactosamine, 1 mM), and platelet aggregation was monitored. Furthermore, the effects of Glucosamine on the thromboxane A2 production, release of granule contents, intracellular calcium mobilization and phosphorylation of Syk (a 72 kD protein tyrosine kinase) were evaluated following ADP-stimulation. In addition, the binding of [^3H] ADP to its receptors was examined. Results: Glucosamine (>0.01 mM) dose-dependently suppressed platelet aggregation in response to ADP ( p < 0.05), whereas N-acetyl-Glucosamine, galactosamine or N-acetyl-galactosamine (1 mM) did not affect the ADP-induced platelet aggregation. Furthermore, Glucosamine (>0.1 mM) inhibited the extracellular release of granule contents (ATP and platelet factor 4) and production of thromboxane A_2 from ADP-stimulated platelets ( p < 0.05). Moreover, Glucosamine significantly repressed the intracellular calcium mobilization at >0.1 mM and phosphorylation of Syk at >0.01 mM upon ADP-stimulation ( p < 0.05). In addition, Glucosamine (>0.1 mM) inhibited the binding of ADP to its receptors ( p < 0.05). Conclusion: Glucosamine is able to suppress platelet aggregation, release of granule constituents, thromboxane A_2 production, calcium mobilization and phosphorylation of Syk possibly via the inhibition of ADP-binding to the receptors. Glucosamine could be expected as a novel anti-platelet agent for thrombotic disorders due to its suppressive actions on platelets.
-
Inhibitory actions of Glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils
Journal of Leukocyte Biology, 2002Co-Authors: Koji Sakamoto, Isao NagaokaAbstract:: Glucosamine, an amino monosaccharide naturally occurring in the connective and cartilage tissues, contributes to maintaining the strength, flexibility, and elasticity of these tissues. In recent years, Glucosamine has been used widely to treat osteoarthritis in humans and animal models. Neutrophils, which usually function as the primary defenders in bacterial infections, are also implicated in the destructive, inflammatory responses in arthritis. In this study, we have evaluated the effects of Glucosamine on neutrophil functions using human peripheral blood neutrophils. Glucosamine (0.01-1 mM) dose-dependently suppressed the superoxide anion generation induced by formyl-Met-Leu-Phe (fMLP) or complement-opsonized zymosan and inhibited the phagocytosis of complement-opsonized zymosan or IgG-opsonized latex particles. Furthermore, Glucosamine inhibited the release of granule enzyme lysozyme from phagocytosing neutrophils and suppressed neutrophil chemotaxis toward zymosan-activated serum. In addition, Glucosamine inhibited fMLP-induced up-regulation of CD11b significantly, polymerization of actin, and phosphorylation of p38 mitogen-activated protein kinase (MAPK). In contrast, N-acetyl-Glucosamine, an analogue of Glucosamine, did not affect these neutrophil functions (superoxide generation, phagocytosis, granule enzyme release, chemotaxis, CD11b expression, actin polymerization, and p38 MAPK phosphorylation) at the concentrations examined (1-10 mM). Together these observations likely suggest that Glucosamine suppresses the neutrophil functions, thereby possibly exhibiting anti-inflammatory actions in arthritis.
Jeanyves Reginster - One of the best experts on this subject based on the ideXlab platform.
-
different Glucosamine sulfate products generate different outcomes on osteoarthritis symptoms
Annals of the Rheumatic Diseases, 2018Co-Authors: Jeanyves Reginster, Olivier Bruyere, C CooperAbstract:Runhaar and colleagues1 produced an elegant meta-analysis of various Glucosamine-containing products in knee and hip osteoarthritis (OA), based on individual patient data (IPD). Although they were able to access and analyse only 5 out 21 eligible studies, their results are in agreement with most Glucosamine meta-analyses in OA: Glucosamine products other than prescription crystalline Glucosamine sulfate are not effective in hip or knee OA pain and function. Such results, as acknowledged by the Authors, had already been demonstrated in several previous and more comprehensive meta-analyses, including a dedicated Cochrane Review2 and a recent effort by Eriksen et al 3 specifically investigating possible differences in efficacy among Glucosamine products. Indeed, Glucosamine exists in different forms for pharmaceutical use, as extensively reviewed by Altman.4 Among these, Glucosamine hydrochloride (used in three out of …
-
A review of Glucosamine for knee osteoarthritis: why patented crystalline Glucosamine sulfate should be differentiated from other Glucosamines to maximize clinical outcomes
Current medical research and opinion, 2016Co-Authors: Eugene J. Kucharz, Olivier Bruyere, Volodymyr Kovalenko, Sándor Szántó, Cyrus Cooper, Jeanyves ReginsterAbstract:The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm for knee osteoarthritis (OA) recommends symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) first line for the medium to long term management of OA, due to their ability to control pain, improve function, and delay joint structural changes. Among SYSADOAs, Glucosamine is probably the most widely used intervention. In the present review of Glucosamine for knee OA, we have investigated whether the evidence is greater for the patented crystalline Glucosamine sulfate (pCGS) preparation (Rottapharm/Meda) than for other Glucosamine formulations. Glucosamine is actually widely available in many forms, as the prescription-grade pCGS preparation, generic and over-the-counter formulations of Glucosamine sulfate (GS) and food supplements containing Glucosamine hydrochloride (GH), which vary substantially in molecular form, pharmaceutical formulation and dose regimens. Only pCGS is given as a highly bioavailable once daily dose (1500 mg) with a proven pharmacological effect. pCGS consistently reaches the plasma levels of around 10 μM required to inhibit interleukin-1 induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction, compared with sub-therapeutic levels achieved with GH. It is evident, from careful consideration of the evidence base, that only the pCGS formulation of Glucosamine reliably provides an effect size on pain that is higher than that of paracetamol and equivalent to that provided by non-steroidal anti-inflammatory drugs. In comparison, the effect size on pain of non-crystalline GS preparations and GH from randomized controlled trials is repeatedly demonstrated to be zero. In addition, there is evidence that chronic administration of pCGS has disease-modifying effects, with a reduction in the need for total joint replacement surgery lasting for at least 5 years after treatment cessation. Consequently, the pCGS preparation (Rottapharm/Meda) is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression.
-
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis
Drugs & Aging, 2007Co-Authors: Olivier Bruyere, Jeanyves ReginsterAbstract:problem throughout the world. Several entities have been carefully investigated for the symptomatic and structural management of OA. This review evaluates published studies of the effect of Glucosamine salts and chondroitin sulfate preparations on the progression of knee or hip OA. Despite multiple double-blind, controlled clinical trials of the use of Glucosamine and chondroitin sulfate in OA, controversy regarding the efficacy of these agents with respect to symptomatic improvement remains. Several potential confounders, including placebo response, use of prescription medicines versus over-the-counter pills or food supplements, or use of Glucosamine sulfate versus Glucosamine hydrochloride, may have relevance when attempting to interpret the seemingly contradictory results of different clinical trials. The National Institutes of Health-sponsored GAIT (Glucosamine/chondroitin Arthritis Intervention Trial) compared placebo, Glucosamine hydrochloride, chondroitin sulfate, a combination of Glucosamine and chondroitin sulfate and celecoxib in a parallel, blinded 6-month multicentre study of patients with knee OA. This trial showed that Glucosamine hydrochloride and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with OA of the knee. However, exploratory analyses suggest that the combination of Glucosamine hydrochloride and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.
-
long term effects of Glucosamine sulphate on osteoarthritis progression a randomised placebo controlled clinical trial
The Lancet, 2001Co-Authors: Jeanyves Reginster, Rita Deroisy, Lucio Claudio Rovati, Eric Lejeune, Olivier Bruyere, Giampaolo Giacovelli, Yves Henrotin, Jane Dacre, Christiane GossettAbstract:Summary Background Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug Glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. Methods We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral Glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width—ie, at the narrowest point—was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. Findings The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of 0·31 mm (95% CI 0·48 to 0·13). There was no significant joint-space loss in the 106 patients on Glucosamine sulphate: 0·06 mm (0·22 to 0·09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with Glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. Interpretation The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis.
Koji Sakamoto - One of the best experts on this subject based on the ideXlab platform.
-
Recent aspects of the anti-inflammatory actions of Glucosamine
Carbohydrate Polymers, 2011Co-Authors: Isao Nagaoka, Shin Yomogida, Mamoru Igarashi, Y. Ju, Koji SakamotoAbstract:Glucosamine, a naturally occurring amino monosaccharide, is present in the connective and cartilage tissues as a component of glycosaminoglycans. Thus, Glucosamine has been widely used to treat osteoarthritis, a joint disease characterized by cartilage degeneration, in humans. In addition, Glucosamine is expected to exert an anti-inflammatory action, since Glucosamine suppresses inflammatory cell activation. To further extend the anti-inflammatory actions of Glucosamine, we investigated the effects of Glucosamine on synovial cells, endothelial cells and intestinal epithelial cells using in vitro and in vivo systems. Firstly, Glucosamine suppressed the IL-1β-induced activation of synovial cells in vitro. Furthermore, Glucosamine administration repressed synovial cell hyperplasia, cartilage destruction and inflammatory cell infiltration in rat adjuvant arthritis. Secondary, Glucosamine suppressed the TNF-α-induced activation of intestinal epithelial cell HT-29 in vitro. In addition, Glucosamine administration improved the clinical symptoms, and colonic inflammation and tissue injury in dextran sulfate sodium-induced colitis in rats. Finally, Glucosamine suppressed the TNF-α-induced activation of endothelial cells in vitro. Moreover, Glucosamine administration repressed the formation of atherosclerotic lesion and infiltration of inflammatory cells into the lesion in spontaneously hyperlipidemic mice B6 KOR Aposhl. Together these observations support the idea that Glucosamine can function as not only a chondroprotective agent but also an anti-inflammatory molecule in the body.
-
Inhibitory action of Glucosamine on platelet activation in guinea pigs.
Inflammation Research, 2005Co-Authors: J. F. Lu-suguro, Koji Sakamoto, Isao NagaokaAbstract:Objective: Glucosamine, a naturally occurring amino monosaccharide, has been used to treat or prevent osteoarthritis in humans. Recently, we have revealed that Glucosamine inhibits platelet activation in vitro. However, the effect of in vivo administration of Glucosamine has not yet been clarified. In this study, we administered Glucosamine orally to guinea pigs and examined its effects on platelet functions.
-
Inhibitory action of Glucosamine on platelet activation in guinea pigs
Inflammation Research, 2005Co-Authors: J. F. Lu-suguro, Koji Sakamoto, Isao NagaokaAbstract:Objective: Glucosamine, a naturally occurring amino monosaccharide, has been used to treat or prevent osteoarthritis in humans. Recently, we have revealed that Glucosamine inhibits platelet activation in vitro . However, the effect of in vivo administration of Glucosamine has not yet been clarified. In this study, we administered Glucosamine orally to guinea pigs and examined its effects on platelet functions. Materials and methods: Glucosamine hydrochloride solution (0.5%, 5 mg/ml) was administered orally to guinea pigs ad libitum for 22 days, and platelet rich plasma was collected to evaluate platelet functions in vitro . Guinea pigs received an average of 400 mg Glucosamine/animal/day. Results: Glucosamine-administration suppressed platelet aggregation in response to ADP by 51% ( p
-
Glucosamine, a naturally occurring amino monosaccharide, suppresses the ADP-mediated platelet activation in humans
Inflammation Research, 2004Co-Authors: S Suguro, Y. Tsutsumi-ishii, Kazuhisa Iwabuchi, Koji Sakamoto, Isao NagaokaAbstract:Objective: To evaluate the anti-thrombotic action of Glucosamine, a naturally occurring amino monosaccharide, platelets were stimulated with ADP in the presence of Glucosamine, and its effects on platelet functions were examined. Materials and Methods: Human platelet-rich plasma was stimulated with 2.5 μM ADP in the presence of Glucosamine (0.01 ~ 1 mM) or other aminosugars (N-acetyl-Glucosamine, galactosamine or N-acetyl-galactosamine, 1 mM), and platelet aggregation was monitored. Furthermore, the effects of Glucosamine on the thromboxane A2 production, release of granule contents, intracellular calcium mobilization and phosphorylation of Syk (a 72 kD protein tyrosine kinase) were evaluated following ADP-stimulation. In addition, the binding of [^3H] ADP to its receptors was examined. Results: Glucosamine (>0.01 mM) dose-dependently suppressed platelet aggregation in response to ADP ( p < 0.05), whereas N-acetyl-Glucosamine, galactosamine or N-acetyl-galactosamine (1 mM) did not affect the ADP-induced platelet aggregation. Furthermore, Glucosamine (>0.1 mM) inhibited the extracellular release of granule contents (ATP and platelet factor 4) and production of thromboxane A_2 from ADP-stimulated platelets ( p < 0.05). Moreover, Glucosamine significantly repressed the intracellular calcium mobilization at >0.1 mM and phosphorylation of Syk at >0.01 mM upon ADP-stimulation ( p < 0.05). In addition, Glucosamine (>0.1 mM) inhibited the binding of ADP to its receptors ( p < 0.05). Conclusion: Glucosamine is able to suppress platelet aggregation, release of granule constituents, thromboxane A_2 production, calcium mobilization and phosphorylation of Syk possibly via the inhibition of ADP-binding to the receptors. Glucosamine could be expected as a novel anti-platelet agent for thrombotic disorders due to its suppressive actions on platelets.
-
Inhibitory actions of Glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils
Journal of Leukocyte Biology, 2002Co-Authors: Koji Sakamoto, Isao NagaokaAbstract:: Glucosamine, an amino monosaccharide naturally occurring in the connective and cartilage tissues, contributes to maintaining the strength, flexibility, and elasticity of these tissues. In recent years, Glucosamine has been used widely to treat osteoarthritis in humans and animal models. Neutrophils, which usually function as the primary defenders in bacterial infections, are also implicated in the destructive, inflammatory responses in arthritis. In this study, we have evaluated the effects of Glucosamine on neutrophil functions using human peripheral blood neutrophils. Glucosamine (0.01-1 mM) dose-dependently suppressed the superoxide anion generation induced by formyl-Met-Leu-Phe (fMLP) or complement-opsonized zymosan and inhibited the phagocytosis of complement-opsonized zymosan or IgG-opsonized latex particles. Furthermore, Glucosamine inhibited the release of granule enzyme lysozyme from phagocytosing neutrophils and suppressed neutrophil chemotaxis toward zymosan-activated serum. In addition, Glucosamine inhibited fMLP-induced up-regulation of CD11b significantly, polymerization of actin, and phosphorylation of p38 mitogen-activated protein kinase (MAPK). In contrast, N-acetyl-Glucosamine, an analogue of Glucosamine, did not affect these neutrophil functions (superoxide generation, phagocytosis, granule enzyme release, chemotaxis, CD11b expression, actin polymerization, and p38 MAPK phosphorylation) at the concentrations examined (1-10 mM). Together these observations likely suggest that Glucosamine suppresses the neutrophil functions, thereby possibly exhibiting anti-inflammatory actions in arthritis.
Olivier Bruyere - One of the best experts on this subject based on the ideXlab platform.
-
different Glucosamine sulfate products generate different outcomes on osteoarthritis symptoms
Annals of the Rheumatic Diseases, 2018Co-Authors: Jeanyves Reginster, Olivier Bruyere, C CooperAbstract:Runhaar and colleagues1 produced an elegant meta-analysis of various Glucosamine-containing products in knee and hip osteoarthritis (OA), based on individual patient data (IPD). Although they were able to access and analyse only 5 out 21 eligible studies, their results are in agreement with most Glucosamine meta-analyses in OA: Glucosamine products other than prescription crystalline Glucosamine sulfate are not effective in hip or knee OA pain and function. Such results, as acknowledged by the Authors, had already been demonstrated in several previous and more comprehensive meta-analyses, including a dedicated Cochrane Review2 and a recent effort by Eriksen et al 3 specifically investigating possible differences in efficacy among Glucosamine products. Indeed, Glucosamine exists in different forms for pharmaceutical use, as extensively reviewed by Altman.4 Among these, Glucosamine hydrochloride (used in three out of …
-
A review of Glucosamine for knee osteoarthritis: why patented crystalline Glucosamine sulfate should be differentiated from other Glucosamines to maximize clinical outcomes
Current medical research and opinion, 2016Co-Authors: Eugene J. Kucharz, Olivier Bruyere, Volodymyr Kovalenko, Sándor Szántó, Cyrus Cooper, Jeanyves ReginsterAbstract:The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm for knee osteoarthritis (OA) recommends symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) first line for the medium to long term management of OA, due to their ability to control pain, improve function, and delay joint structural changes. Among SYSADOAs, Glucosamine is probably the most widely used intervention. In the present review of Glucosamine for knee OA, we have investigated whether the evidence is greater for the patented crystalline Glucosamine sulfate (pCGS) preparation (Rottapharm/Meda) than for other Glucosamine formulations. Glucosamine is actually widely available in many forms, as the prescription-grade pCGS preparation, generic and over-the-counter formulations of Glucosamine sulfate (GS) and food supplements containing Glucosamine hydrochloride (GH), which vary substantially in molecular form, pharmaceutical formulation and dose regimens. Only pCGS is given as a highly bioavailable once daily dose (1500 mg) with a proven pharmacological effect. pCGS consistently reaches the plasma levels of around 10 μM required to inhibit interleukin-1 induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction, compared with sub-therapeutic levels achieved with GH. It is evident, from careful consideration of the evidence base, that only the pCGS formulation of Glucosamine reliably provides an effect size on pain that is higher than that of paracetamol and equivalent to that provided by non-steroidal anti-inflammatory drugs. In comparison, the effect size on pain of non-crystalline GS preparations and GH from randomized controlled trials is repeatedly demonstrated to be zero. In addition, there is evidence that chronic administration of pCGS has disease-modifying effects, with a reduction in the need for total joint replacement surgery lasting for at least 5 years after treatment cessation. Consequently, the pCGS preparation (Rottapharm/Meda) is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression.
-
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis
Drugs & Aging, 2007Co-Authors: Olivier Bruyere, Jeanyves ReginsterAbstract:problem throughout the world. Several entities have been carefully investigated for the symptomatic and structural management of OA. This review evaluates published studies of the effect of Glucosamine salts and chondroitin sulfate preparations on the progression of knee or hip OA. Despite multiple double-blind, controlled clinical trials of the use of Glucosamine and chondroitin sulfate in OA, controversy regarding the efficacy of these agents with respect to symptomatic improvement remains. Several potential confounders, including placebo response, use of prescription medicines versus over-the-counter pills or food supplements, or use of Glucosamine sulfate versus Glucosamine hydrochloride, may have relevance when attempting to interpret the seemingly contradictory results of different clinical trials. The National Institutes of Health-sponsored GAIT (Glucosamine/chondroitin Arthritis Intervention Trial) compared placebo, Glucosamine hydrochloride, chondroitin sulfate, a combination of Glucosamine and chondroitin sulfate and celecoxib in a parallel, blinded 6-month multicentre study of patients with knee OA. This trial showed that Glucosamine hydrochloride and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with OA of the knee. However, exploratory analyses suggest that the combination of Glucosamine hydrochloride and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.
-
long term effects of Glucosamine sulphate on osteoarthritis progression a randomised placebo controlled clinical trial
The Lancet, 2001Co-Authors: Jeanyves Reginster, Rita Deroisy, Lucio Claudio Rovati, Eric Lejeune, Olivier Bruyere, Giampaolo Giacovelli, Yves Henrotin, Jane Dacre, Christiane GossettAbstract:Summary Background Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug Glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. Methods We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral Glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width—ie, at the narrowest point—was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. Findings The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of 0·31 mm (95% CI 0·48 to 0·13). There was no significant joint-space loss in the 106 patients on Glucosamine sulphate: 0·06 mm (0·22 to 0·09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with Glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. Interpretation The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis.
Yoshihiko Hayashi - One of the best experts on this subject based on the ideXlab platform.
-
d -Glucosamine contributes to cell membrane stability and regenerative medicine
Environmental Chemistry Letters, 2019Co-Authors: Yoshihiko HayashiAbstract:d-Glucosamine contributes to cell membrane stability. d-Glucosamine controls biological responses and protect both cells and tissues. This review focuses the mechanisms of stability in biomedical situations. Positively charged amino groups of d-Glucosamine can bind the cell membrane electrically to protect against tissue damage. Wound healing can be accelerated by the application of a d-Glucosamine dressing, which promotes cell proliferation and differentiation. d-Glucosamine has superoxide/hydroxyl radical scavenging activities, a strong chelating effect on ferrous ions, and enhances the reduced glutathione level to promote activity against intracellular oxidative stress. The prompt repair of microleakage through electropores on the cell membrane occurs after electroporation using d-Glucosamine. The effects of this stability can also explain the pain relief as d-Glucosamine binds to sodium channel to result in a longer open time. Furthermore, specific applications of d-Glucosamine are proposed for the regenerative medicine.
-
The Contribution of D-Glucosamine to Cell Membrane Stability: Mechanisms and Applications in Regenerative Medicine
Sustainable Agriculture Reviews 35, 2019Co-Authors: Yoshihiko HayashiAbstract:Chitosan is a well-known biomaterial. D-Glucosamine, which consists of a natural amino monosaccharide, is the smallest molecular weight of chitosan. D-Glucosamine is widely used for relieving the pain associated with osteoarthritis. It has recently been confirmed that D-Glucosamine contributes to cell membrane stability in the biomedical field. D-Glucosamine may control biological responses and protect both cells and tissues. This chapter briefly focuses the mechanisms of this stability in several important biomedical situations. Positive charged amino groups of D-Glucosamine can bind the cell membrane electrically to protect against tissue damage. Wound healing can be accelerated by the application of a D-Glucosamine dressing, which promotes cell proliferation and differentiation. D-Glucosamine has superoxide/hydroxyl radical scavenging activities and a strong chelating effect on ferrous ions, and enhances the reduced glutathione level to promote activity against intracellular oxidative stress. The early and prompt repair of microleakage through electropores on the cell membrane occurs after electroporation using D-Glucosamine. The effects of this stability can also explain the pain relief as D-Glucosamine binds to sodium channel to result in a longer open time. Furthermore, specific applications of D-Glucosamine are proposed for the regenerative medicine.